Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s New Head Of Orphan And Genetic Diseases Looks To Shake Up The Big Pharma Problem-Solving Model

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer’s new head of orphan and genetic diseases, Kevin Lee, aims to build a capability within the Big Pharma that is specifically focused on rare diseases, employing a “partner by first intent” problem solving philosophy that reaches across other internal units and across the scientific community.

You may also be interested in...

Precision Medicine Will Be In Action At ASCO

Though the tracks and sessions are still named largely for organs and other phenotypic descriptions of cancer, the notion of basing treatments on the molecular drivers of a tumor alone is pervasive at this year’s meeting of the American Society of Clinical Oncology, June 1-5 in Chicago.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal

President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts